Lexaria's Patented Technology Improved The Oral Performance Of The Rybelsus-Branded GLP-1 Drug Semaglutide
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp. announced positive results from a human pilot study showing its DehydraTECH technology improved the oral delivery of the GLP-1 drug semaglutide, branded as Rybelsus. The study, conducted by a university research center, demonstrated that DehydraTECH-powered semaglutide achieved higher blood levels, better blood glucose control, faster peak drug delivery, and reduced side effects compared to the control. Lexaria is preparing for further studies to evaluate DehydraTECH's effectiveness with GLP-1 drugs.
January 04, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience's positive study results for DehydraTECH technology could lead to increased investor confidence and potential stock price appreciation in the short term.
The positive results from the pilot study are significant for Lexaria as they demonstrate the potential of DehydraTECH technology to improve the delivery and efficacy of GLP-1 drugs like Rybelsus. This could lead to increased interest from investors and potential partnerships or licensing deals, which may positively impact the stock price in the short term. The confidence score is not at the maximum due to the early stage of the study and the need for further research to confirm these findings.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100